
Zidesamtinib Produces Durable Responses in TKI-Pretreated, ROS1+ NSCLC
The novel, brain-penetrant, selective ROS1 inhibitor zidesamtinib (NVL-520) was well tolerated and yielded durable responses in patients with advanced ROS1-positive non–small cell lung cancer (NSCLC) previously treated with at least 1 TKI, according to …